For the Quarter Ending September 2025
North America
• In USA, the Amlodipine Besylate Price Index rose by 1.37% quarter-over-quarter, driven by importer frontloading.
• The average Amlodipine Besylate price for the quarter was approximately USD 71693.33/MT on CFR shipments.
• Amlodipine Besylate Spot Price displayed limited volatility despite import surges and intermittent port congestion periods.
• Amlodipine Besylate Price Forecast suggests modest gains as distributors replenish inventories cautiously over months ahead.
• Amlodipine Besylate Production Cost Trend rose due to higher freight, handling, and raw material costs.
• Amlodipine Besylate Demand Outlook remains steady with strategic forward buying sustaining near-term firm consumption levels.
• Distributor inventories tightened temporarily, pressuring the Amlodipine Besylate Price Index across major US distribution hubs.
• Logistics disruptions and seasonal congestion increased landed costs, prompting sellers to sustain firm pricing levels.
Why did the price of Amlodipine Besylate change in September 2025 in North America?
• Importer frontloading ahead of tariff uncertainty concentrated orders, creating short-term demand spikes and market tightening.
• Rising freight and handling costs elevated landed costs, supporting higher domestic pricing and supplier margins.
• Port congestion and weather disruptions delayed shipments, reducing immediate supply availability and amplifying distribution bottlenecks.
APAC
• In China, the Amlodipine Besylate Price Index rose by 1.426% quarter-over-quarter in Q3 2025, frontloaded export activity.
• The average Amlodipine Besylate price for the quarter was approximately USD 71596.67/MT, FOB Shanghai levels.
• Amlodipine Besylate Spot Price firmed on tightened logistics and stronger export orders, reducing available spot market volumes.
• Amlodipine Besylate Price Forecast indicates gradual increases through late autumn as frontloaded shipments normalize and inventories adjust.
• Amlodipine Besylate Production Cost Trend rose with higher freight rates and weather-related operational disruptions raising unit supply costs.
• Amlodipine Besylate Demand Outlook remains supportive due to international restocking and advanced orders ahead of tariff reinstatement.
• Amlodipine Besylate Price Index volatility moderated as exporters drew down June–August stocks, easing near-term supply pressures.
• Port congestion and vessel space shortages intermittently pushed small spot price spikes and encouraged aggressive booking by exporters.
• Manufacturers kept output conservative, avoiding capacity expansion while aligning batches for holidays, supporting modest sustained price increases.
Why did the price of Amlodipine Besylate change in September 2025 in APAC?
• Frontloaded export orders increased short-term demand, tightening availability and prompting suppliers to raise prices slightly.
• Rising ocean freight rates and port congestion elevated logistics costs, pushing up delivered production prices.
• Temporary tariff suspension accelerated shipments; once suspension ends, buying patterns likely to normalize, reducing urgency.
Europe
• In Germany, the Amlodipine Besylate Price Index rose by 1.44% quarter-over-quarter, driven by port congestion.
• The average Amlodipine Besylate price for the quarter was approximately USD 71700.00/MT as reported locally.
• Amlodipine Besylate Spot Price tightened as early restocking and freight surcharges reduced available spot volumes.
• Amlodipine Besylate Price Forecast shows modest near-term gains as logistics improve and demand stabilizes seasonally.
• Amlodipine Besylate Production Cost Trend remains stable with limited feedstock inflation and higher transport-related overheads.
• Amlodipine Besylate Demand Outlook is steady with cautious restocking by wholesalers and healthcare providers nationwide.
• Amlodipine Besylate Price Index reflected tight inventories and constrained exports amid berth delays and rerouting.
• Adjusted carrier schedules ease shipments, fostering supply normalization and reducing short-term price volatility overcoming delays.
Why did the price of Amlodipine Besylate change in September 2025 in Europe?
• Persistent Northern European port congestion prolonged berth times, delaying shipments and tightening local supply availability.
• Elevated freight surcharges and rerouting increased landed costs and lead times, pressuring procurement and margins.
• Advance restocking by wholesalers and healthcare providers reduced spot availability, amplifying short-term upward price pressure.
For the Quarter Ending June 2025
North America
• The Amlodipine Besylate Spot Price in the U.S. increased marginally in April (+0.25%), dropped sharply in May (-2.77%), and rebounded slightly in June (+0.64%), with the Price Index reaching USD 70,360/MT (CFR Los Angeles) by the end of Q2.
• April’s increase was primarily driven by a rush in API procurement due to the 145% U.S. tariff on Chinese goods, encouraging buyers to frontload orders and stockpile inventories ahead of expected cost hikes.
• Strong importer demand and rerouted logistics contributed to tighter supply and a firm Amlodipine Besylate Demand Outlook, even as the inflation backdrop remained surprisingly soft.
• In May, price levels fell sharply as buyers paused purchasing to reassess inventory levels and pricing after a 90-day trade truce and partial rollback of some tariffs were announced mid-month.
• A significant regulatory development in May—the introduction of the “Most Favored Nation” pricing policy—created hesitation, compelling buyers to delay restocking and reducing procurement activity.
• In June, prices edged up as companies resumed imports to pre-empt any tariff escalation post-truce. Forward purchasing increased, especially from formulators aiming to lock in prices for H2 2025.
• Logistics operated efficiently throughout Q2, allowing pre-truce procurement strategies to play out with minimal delays across U.S. ports.
• The Amlodipine Besylate Price Forecast for early Q3 suggests stability with slight downside potential if trade clarity improves and inventory stock remains high.
• July 2025 prices likely declined modestly, influenced by reduced urgency in buying, improved confidence in stable U.S.–China trade ties, and full warehouses from aggressive Q2 stocking.
APAC
• The Amlodipine Besylate Spot Price in China witnessed a marginal increase in April (+0.28%) and June (+0.53%), while May saw a significant decline of -2.79%, reflecting mixed fundamentals across the quarter.
• In April, the Price Index rose to USD 71,800/MT (FOB Shanghai) as pre-tariff frontloading in global markets, particularly the U.S., supported export demand and tightened Chinese availability.
• The Amlodipine Besylate Demand Outlook from international buyers remained firm in April, especially due to the impending U.S. tariff, which pushed exporters to raise prices slightly amid logistical adjustments.
• A sharp price correction occurred in May as frontloaded orders tapered and domestic suppliers responded with lower quotations amidst reduced international offtake and improving inventories.
• In June, the Price Index edged up by 0.53% to USD 70,170/MT, driven by proactive reordering from overseas buyers ahead of any further geopolitical shifts and mild recovery in global API demand.
• The Amlodipine Besylate Production Cost Trend in China remained stable throughout Q2, with raw material costs and energy inputs showing no major fluctuations.
• Improved shipping schedules and stable inland logistics allowed for smooth cargo movement in May–June, preventing any bottlenecks despite external policy concerns.
• By quarter-end, Chinese exporters held relatively manageable inventories, although order visibility for Q3 remained moderate amid rising competition from alternate API suppliers in India and Southeast Asia.
• The Amlodipine Besylate Price Forecast for July suggested slight pressure on prices due to softened global offtake and elevated post-truce inventories.
• July 2025 prices likely decreased marginally in China as frontloaded Q2 shipments and easing export orders led to restrained spot quotations across key trade hubs.
Europe
• The Amlodipine Besylate Spot Price in Germany mirrored global trends with a slight rise in April (+0.29%), a dip in May (-2.80%), and a mild rebound in June (+0.57%) to reach USD 70,280/MT (CFR Hamburg).
• April’s gains were supported by elevated global demand and pre-emptive ordering by European pharmaceutical distributors who responded to cost uncertainty linked to U.S.–China tariffs.
• The Amlodipine Besylate Demand Outlook in Germany remained stable through April as formulators actively participated in global procurement cycles to ensure continuity of supply amid global trade dislocation.
• May recorded the steepest monthly decline as improved availability from Asia and reduced downstream urgency led to inventory normalization and price corrections.
• The Amlodipine Besylate Production Cost Trend in Europe remained steady throughout Q2, with most cost changes driven by imported material prices rather than local processing.
• June saw a rebound in prices due to anticipated supply constraints in Q3 and proactive import activity by European distributors hedging against external disruptions.
• As with the U.S., many German buyers advanced their procurement timelines to mitigate future volatility, leading to early demand bunching in late Q2.
• Port operations and container logistics across North Europe ran smoothly, enabling timely delivery of forward-booked cargoes from Asia.
• The Amlodipine Besylate Price Forecast for early Q3 indicates possible softening, given excess inventories and a weaker-than-usual restocking pattern from smaller distributors.
• July 2025 prices likely decline due to the combination of high stock levels, eased pressure from Asian exporters, and conservative procurement across the EU pharmaceutical sector.
For the Quarter Ending March 2025
North America
During Q1 2025, Amlodipine Besylate prices in the U.S. experienced fluctuating trends shaped by trade policy shifts, supply chain dynamics, and varying demand. In January, prices moderately increased as importers rushed to secure shipments ahead of the proposed 10% tariff on Chinese goods set for February. This surge in procurement, compounded by the upcoming Chinese Lunar New Year and rising energy costs, strained supply chains and elevated prices. Port congestion in Los Angeles, worsened by wildfire-related disruptions, further delayed shipments and pushed operational costs higher.
However, February saw a decline in prices due to improved Chinese production after the holiday and reduced transpacific freight rates, enhancing supply flow into the U.S. Demand weakened as economic uncertainty and prior stockpiling discouraged fresh purchases. By March, prices rose slightly amid renewed buying activity, as President Trump’s March 4 tariff actions on major trading partners reignited concerns over pharmaceutical supply disruptions. With more tariffs anticipated in April, market participants frontloaded procurement. Eased consumer inflation slightly improved sentiment, adding to the firming trend.
Overall, Q1 reflected a volatile but resilient pricing environment, driven by geopolitical and logistical factors.
Asia Pacific
In Q1 2025, the Amlodipine Besylate market in China saw notable price fluctuations driven by shifting supply and demand dynamics. In January, prices increased due to rising demand from the pharmaceutical and healthcare sectors, along with supply constraints caused by the Lunar New Year holiday, which reduced manufacturing output. Additionally, exporters rushed to frontload shipments ahead of anticipated U.S. tariffs, tightening supply and fueling bullish market sentiment. In February, prices slightly declined as supply stabilized. Manufacturing activity improved post-holiday, boosting production capacity, while demand remained weak due to deflationary pressures, limited consumer spending, and sluggish activity in the pharmaceutical sector. The impact of U.S. tariffs also led to higher domestic inventories as exporters shifted focus to local markets. By March, prices increased modestly as supply struggled to meet sustained demand. Low inventory levels, accelerated procurement from foreign buyers due to trade uncertainties, and stronger domestic demand, driven by fiscal stimulus and restocking before plant maintenance, all contributed to tightening market conditions. Overall, the quarter saw a moderate price increase, influenced by varying supply constraints and demand shifts.
Europe
In Q1 2025, Amlodipine Besylate prices in Germany saw significant fluctuations driven by a mix of demand, supply conditions, and external factors. January experienced a moderate price increase, bolstered by an improvement in German business morale and favorable monetary policy, which boosted demand from the healthcare and pharmaceutical sectors. Early stockpiling due to supply chain delays caused by the Lunar New Year further pressured prices upwards. However, February saw a price decline, as ample supply and weak demand resulted in less urgency for new orders. The appreciation of the Euro against the US Dollar and a sharp drop in freight rates allowed for cost-effective imports, leading to an inventory buildup. In contrast, March saw prices rise again as supply constraints intensified, driven by port congestion and labor unrest across Europe, affecting shipments. Restocking activity resumed, and increased confidence in the pharmaceutical sector fueled demand, leading to a price recovery. By the end of Q1, Amlodipine Besylate prices had shown a moderate upward trend, with a stronger outlook for the coming months.
For the Quarter Ending December 2024
North America
During Q4 2024, Amlodipine Besylate prices in the USA exhibited dynamic shifts, driven by evolving market conditions. Prices surged in October due to heightened demand, fueled by Federal Reserve rate cuts that bolstered consumer confidence. Prolonged port congestion, labor strikes, and fears of tariff hikes under President-elect Donald Trump disrupted supply chains, exacerbating supply-demand imbalances and driving prices upward.
In November, prices slightly declined as demand softened amidst inflationary pressures and high interest rates. The appreciation of the U.S. dollar reduced import costs, while the resolution of the ILA strike eased logistics. These factors, combined with healthy inventories, allowed suppliers to lower prices, passing on savings to consumers.
By December, Amlodipine Besylate prices fell further due to dampened consumer confidence, seasonal demand slowdowns, and proactive inventory buildup ahead of potential January strikes and the Chinese Lunar New Year. Inflation concerns and tariff uncertainties prompted cautious buying, while ample supply and competitive pricing strategies added downward pressure. Overall, Q4 showcased a volatile market that ultimately trended downward. As of the end of Q4, Amlodipine Besylate was priced at USD 72,800 per metric ton (USP, FDA) CFR Los Angeles.
Asia Pacific
In Q4 2024, the Amlodipine Besylate market in China showcased a dynamic pricing trend influenced by varying economic and market factors. In October, prices rose significantly, driven by the resurgence of China's manufacturing sector following government stimulus measures. Increased domestic and export demand, coupled with monetary easing and a depreciated yuan, bolstered consumer confidence and external orders, enabling suppliers to raise prices.
However, this upward momentum reversed in November as high inventory levels, slowing domestic demand, and weak international orders, particularly from the USA and Europe, led to oversupply and cautious market sentiment. Falling crude oil prices further reduced operational costs, prompting manufacturers to lower prices to remain competitive.
In December, prices declined further due to subdued consumer demand amid China’s ongoing disinflation. Pharmaceutical companies and international buyers adjusted procurement strategies, contributing to weaker demand. Additionally, reduced foreign orders during the holiday season left suppliers with excess stock, forcing price cuts to clear inventories before year-end. Overall, Q4 reflected a shift from price gains in October to declines in the subsequent months due to fluctuating demand and market conditions. By the end of Q4, Amlodipine Besylate was priced at USD 70800 per metric ton in China.
Europe
In Q4 2024, Amlodipine Besylate prices in Germany exhibited contrasting trends across the months. October saw a significant price increase driven by improved business morale, bolstered by optimism around economic recovery and the European Central Bank’s third interest rate cut to 3.25%. This policy spurred spending and investment, while preemptive inventory buildup and supply chain challenges, including delays at Hamburg’s ports, added upward pressure.
However, November marked a downturn as weak end-sector demand and fading inflation concerns subdued price pressures. A sharp decline in consumer spending and retail performance in Germany, coupled with a 1.9% drop in energy prices, reduced operational costs and allowed suppliers to offer competitive rates.
The downward trend persisted into December due to weak demand from key sectors, cautious buyer behavior amid inflation concerns, and increased import costs due to the euro’s depreciation. Ample inventories and year-end stock clearance efforts further weighed on prices, while harsh winter conditions slowed consumer activity and logistics, exacerbating the decline. Overall, Q4 reflected a shift from initial optimism to economic caution, impacting price dynamics. By the end of Q4, Amlodipine Besylate was priced at USD 72610 per metric ton (USP, FDA) CFR Hamburg.
